Sarepta doubles down on gene therapies after early Limb-Girdle data
February 27, 2019 at 10:48 AM EST
Sarepta (NASDAQ: SRPT) revealed Wednesday that the first three patients dosed in an early stage trial exceeded the company’s hopes for its Limb-Girdle Muscular Dystrophy drug.
